Neuroscientific Biopharmaceuticals Ltd has released a press release.
Results from Pulmonary Studies
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Earlier from Neuroscientific Biopharmaceuticals
- Quarterly Update and Appendix 4C
- Successful completion of pivotal ocular safety study
- NSB partners with Linear Research for Phase I Clinical Study
- R&D Tax Rebate Received
- Update on Pivotal Ocular Safety Studies
Later from Neuroscientific Biopharmaceuticals
- Pause in Trading
- Results from Pulmonary Studies Clarification
- 2021 Annual Report and Appendix 4E
- Positive Results in Multiple Sclerosis Study
- NSB Receives R&D Advance & Overseas Finding
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals